Xcytrin motexafin gadolinium regulatory update

Pharmacyclics received an FDA not approvable letter for an NDA for Xcytrin motexafin gadolinium for use in combination with radiotherapy to treat non-small cell lung cancer (NSCLC) patients with brain...